{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:22:38Z","timestamp":1787757758579,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Ataxia\u2013telangiectasia (AT) is a type of primary immunodeficiency characterized by an autosomal recessive mode of inheritance and usually presents with progressive cerebellar ataxia in early life. This complex disease is associated with humoral and cellular immune dysfunction and other features including characteristic oculocutaneous telangiectasia and increased predisposition to cancers, particularly lymphoma and leukemia. An 11-year-old Iranian girl presented with primary immunodeficiency and was diagnosed as having AT according to her clinical manifestations and molecular findings. She had a history of two types of non-Hodgkin's lymphoma and showed spontaneous regression of her diffuse large B-cell lymphoma without any specific treatment. Gene mutations and dysfunction in patients with AT result in different manifestations including abnormal development of the thymus, immunodeficiency, increased susceptibility to malignancies, and increased radiosensitivity. No standard treatment is available for these patients. The use of immunotherapeutic strategies in patients with primary immune deficiency disease-associated tumors is potentially important.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/abr.abr_169_21","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:54:15Z","timestamp":1651200855000},"page":"31","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Spontaneous Regression of Diffuse Large B-cell Lymphoma in a Patient with Ataxia\u2013Telangiectasia"],"prefix":"10.4103","volume":"11","author":[{"given":"Roya","family":"Sherkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Afshar Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Reisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-31-20240830","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13023-016-0543-7","article-title":"Ataxia telangiectasia: A review","volume":"11","author":"Rothblum-Oviatt","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"R2-31-20240830","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.dnarep.2004.04.010","article-title":"Ataxia-telangiectasia, an evolving phenotype","volume":"3","author":"Chun","year":"2004","journal-title":"DNA Repair (Amst"},{"key":"R3-31-20240830","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1017\/S0317167100007794","article-title":"Ataxia-telangiectasia: Atypical presentation and toxicity of cancer treatment","volume":"36","author":"Yanofsky","year":"2009","journal-title":"Can J Neurol Sci"},{"key":"R4-31-20240830","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2249.2008.03684.x","article-title":"Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene","volume":"153","author":"Staples","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"R5-31-20240830","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3389\/fimmu.2018.03136","article-title":"Primary immunodeficiency and cancer predisposition revisited: Embedding two closely related concepts into an integrative conceptual framework","volume":"9","author":"Haas","year":"2018","journal-title":"Front Immunol"},{"key":"R6-31-20240830","first-page":"5","article-title":"Epidemiology of Non-Hodgkin's Lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel"},{"key":"R7-31-20240830","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CMAR.S34273","article-title":"Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma-novel and emerging therapies","volume":"5","author":"Chao","year":"2013","journal-title":"Cancer Manag Res"},{"key":"R8-31-20240830","doi-asserted-by":"crossref","first-page":"e28091","DOI":"10.1002\/pbc.28091","article-title":"Malignancy and lymphoid proliferation in primary immune deficiencies; hard to define, hard to treat","volume":"67","author":"Kiykim","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R9-31-20240830","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13256-018-1937-z","article-title":"Spontaneous remission in diffuse large cell lymphoma: A case report","volume":"13","author":"Snijder","year":"2019","journal-title":"J Med Case Rep"},{"key":"R10-31-20240830","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12885-020-07749-6","article-title":"The association between ATM variants and risk of breast cancer: A systematic review and meta-analysis","volume":"21","author":"Moslemi","year":"2021","journal-title":"BMC Cancer"},{"key":"R11-31-20240830","first-page":"D25","article-title":"Primary diffuse large B-cell lymphoma arising in the tongue accompanied by ataxia-telangiectasia: A case report","volume":"9","author":"Tomioka","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"R12-31-20240830","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/MPH.0b013e3182804d59","article-title":"Successful treatment of diffuse large B-cell lymphoma in a patient with ataxia telangiectasia using rituximab","volume":"35","author":"Machida","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"R13-31-20240830","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/2326-6066.CIR-14-0173","article-title":"Three steps to breaking immune tolerance to lymphoma: A microparticle approach","volume":"3","author":"Makkouk","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R14-31-20240830","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3960\/jslrt.47.23","article-title":"Spontaneous regression of diffuse large B-cell lymphoma harbouring Epstein-Barr virus: A case report and review of the literature","volume":"47","author":"Abe","year":"2007","journal-title":"J Clin Exp Hematop"},{"key":"R15-31-20240830","doi-asserted-by":"crossref","first-page":"e1386829","DOI":"10.1080\/2162402X.2017.1386829","article-title":"Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics","volume":"6","author":"Garg","year":"2017","journal-title":"Oncoimmunology"},{"key":"R16-31-20240830","doi-asserted-by":"crossref","first-page":"e1446720","DOI":"10.1080\/2162402X.2018.1446720","article-title":"Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome- microbubble complexes","volume":"7","author":"Huang","year":"2018","journal-title":"Oncoimmunology"},{"key":"R17-31-20240830","doi-asserted-by":"crossref","first-page":"41600","DOI":"10.18632\/oncotarget.6113","article-title":"Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: Impact on clinical studies and considerations for combined therapies","volume":"6","author":"Gebremeskel","year":"2015","journal-title":"Oncotarget"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_169_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:52:41Z","timestamp":1787755961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_169_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_169_21","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}